Welcome to our dedicated page for Hcw Biologics news (Ticker: HCWB), a resource for investors and traders seeking the latest updates and insights on Hcw Biologics stock.
HCW Biologics Inc. develops fusion immunotherapeutics for diseases associated with chronic inflammation, including autoimmune disorders, proinflammatory diseases, cancer and senescence-associated dysplasia. Its recurring company updates center on the TOBI and TRBC discovery platforms and product candidates such as HCW9302, an IL-2 fusion immunotherapeutic, HCW11-018b, a T-cell engager for solid tumors, and HCW9206, a multi-cytokine fusion protein reagent used in CAR-T manufacturing research.
News about HCWB also covers clinical and preclinical program disclosures, research publications, licensing activity involving HCW11-006 and Trimmune, operating and financial results, capital-structure matters, shareholder voting topics and Nasdaq listing-status developments.
HCW Biologics (NASDAQ:HCWB) exercised its option to regain full ex vivo rights to HCW9206 and HCW9201 from Wugen for no cost, while keeping the original upfront license fee and 2.2 million Wugen shares.
HCW9206 is a commercial-ready, multi-cytokine fusion protein reagent that, according to published data, may improve CAR-T and NK-cell manufacturing efficiency, enrich long-lived T-memory stem cells, and potentially enhance persistence and function of CAR-T therapies. The company plans to commercialize these reagents through partners focused on CAR-T and NK-cell therapies.
HCW Biologics (NASDAQ: HCWB) priced a private placement of approximately $4.0 million, selling 2,846,975 units at $1.405 per unit to healthcare investors. Each unit includes one common share (or pre-funded warrant) and one warrant with a $1.28 exercise price.
Net proceeds are earmarked to fund clinical trials for HCW9302, advance IND-enabling studies for HCW11-018b and HCW11-040, cover general corporate purposes, and pay certain debts and settlements.
HCW Biologics (NASDAQ: HCWB) reported Q1 2026 revenue of $6.5 million, driven by an exclusive worldwide license for HCW11-006 to Trimmune, and net income of $3.5 million. R&D and G&A expenses declined 15% and 18% year-over-year.
The company remains on track for preliminary Phase 1 data for HCW9302 in alopecia areata in 1H 2026, with full readout expected in Q4 2026, and reported no dose-limiting toxicities to date. A Science Advances publication highlighted HCW9206 as a potential CAR-T manufacturing reagent.
HCW completed a $1.5 million equity financing in February 2026. Management notes substantial doubt about going-concern status without additional funding, and HCW is appealing a Nasdaq delisting notice related to the $1.00 minimum bid price rule.
HCW Biologics (NASDAQ: HCWB) reported that HCW11-040, a pembrolizumab-based fusion immunotherapeutic, prevented bronchopulmonary dysplasia (BPD) in a stringent animal model during IND-enabling studies. A single subcutaneous dose was effective.
The company expects to complete IND-enabling studies in 2H 2027 and then file an IND for high-risk infants. BPD affects an estimated 10,000–15,000 U.S. premature infants annually, and HCW Biologics believes this indication could align with the reauthorized Rare Pediatric Disease priority review voucher program, funded through September 2029.
HCW Biologics (NASDAQ: HCWB) adjourned its Special Meeting of Stockholders held April 27, 2026, for lack of a quorum; no business was conducted and proposals will be moved to the Annual Meeting on June 15, 2026 at 10:00 a.m. ET.
The company continues to solicit votes on two proposals tied to warrants issued to Armistice Capital Master Fund Ltd., following a $17.4 million investment. The warrants would permit purchase of up to 5,497,702 shares at an exercise price of $0.6055. The company must seek shareholder approval every 60 days and will incur ongoing costs until approval is obtained.
HCW Biologics (NASDAQ: HCWB) reported preclinical results for its tetra-valent T‑Cell Engager HCW11-018b, showing tumor shrinkage and metastasis prevention in xenograft models and a tumor-restricted activation mechanism via cis-binding. The company projects an IND filing in H1 2027 targeting pancreatic and ovarian cancer.
The poster was presented at AACR Annual Meeting 2026 and the company highlights a streamlined GMP manufacturing process to support clinical development.
HCW Biologics (NASDAQ: HCWB) reported Q4 and full-year 2025 results and business highlights on March 31, 2026. Key items: initiation of a Phase 1 trial for HCW9302 on Nov 17, 2025, a Science Advances publication for HCW9206 on Mar 13, 2026, and receipt of a $3.5M upfront license fee (net $2.9M) on Mar 16, 2026.
Financials: 2025 revenue was $54,232 (vs $2.6M in 2024); R&D $5.4M; G&A $7.7M; net loss improved to $6.5M from $30.0M. The company disclosed substantial doubt about going concern as of Dec 31, 2025 and received a Nasdaq bid-price notice on Mar 26, 2026.
HCW Biologics (NASDAQ: HCWB) closed an exclusive worldwide license with Beijing Trimmune Biotech for HCW11-006, receiving a $7.0 million upfront package (a $3.5 million cash payment plus $3.5 million in transferable equity) on March 17, 2026.
Trimmune will fund a Phase 1 China study expected in H1 2027; HCW retains a payment-free option to recapture Americas rights after Phase 1. HCW is eligible for development milestones, double-digit royalties, and proceeds from future transactions.
HCW Biologics (NASDAQ: HCWB) announced publication of preclinical research in Science Advances (March 13, 2026) showing its proprietary reagent HCW9206 generates CAR-T cells highly enriched for long-lived T memory stem cells (Tscm) and with superior anti-tumor and antiviral activity in experimental models.
Authors report HCW9206-produced CAR-Ts reached ≥50% Tscm, showed improved persistence and functional activity against HIV-1 and CD19+ leukemia in humanized animal models, and may offer a streamlined, lower-cost manufacturing alternative to αCD3/28/IL-2 methods.
HCW Biologics (Nasdaq: HCWB) announced that on February 26, 2026 the Nasdaq Hearings Panel found the company regained compliance with all continued listing rules of the Nasdaq Capital Market.
This determination preserves HCWB's access to public capital markets to fund its clinical-stage immunotherapy programs, the company said.